Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir in treatment-experienced chronic hepatitis C
NCT00703118Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2008
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of telaprevir in hepatitis C (HCV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained Virologic Response 24 Weeks After Last Dose at Week 72. Started Oct 2008; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00703118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703118.